TECTONIC THERAPEUTIC, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $44.00K, a 77.32% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $100.00K, a 89.71% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $6.00K, a 92.21% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $194.00K, a 69.88% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.23M, a 24.20% decline from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.62M, a 1242.15% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $121.00K, a 108.62% increase from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $58.00K, a 93.70% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $44.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $100.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.23M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $6.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $194.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $972.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $1.62M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $77.00K 10-Q · filed 2025-11-06 | $670.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $644.00K 10-Q · filed 2025-11-06 | $699.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | $4.00K 10-Q · filed 2025-11-06 | $84.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | -$55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $121.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $106.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $29.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $58.00K 10-K · filed 2024-03-14 | |
| 2021-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $920.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $22.00K 10-Q · filed 2022-11-08 | $986.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.02M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $850.00K 10-Q · filed 2022-05-10 | $1.08M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $270.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $60.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $61.00K 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $35.00K 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $502.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $9.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $238.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $252.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $17.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |